4800 HAMPDEN LANE, BETHESDA, MD
Corporate Presentation September 2024 Parkinson’s Disease KOL Event Biomarkers, Clinical Endpoints, and the Path to Disease Modification
Changes in Board, Management or Compensation
Other Events
Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
Announces Pricing of $7.0 Million Public Offering
News, Articles of Incorporation
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload